乌司奴单抗在溃疡性结肠炎3期随机试验中的药代动力学与暴露-反应关系
该分析基于两项3期试验,纳入中重度溃疡性结肠炎患者,静脉诱导后皮下维持。乌司奴单抗血清浓度与剂量成比例,不受既往生物制剂或免疫调节剂影响,与临床和组织学疗效及炎症标志物正常化相关。诱导应答的周8浓度阈值为3.7 μg/mL,维持期稳态谷浓度≥1.3 μg/mL与更高临床缓解率相关,未发现与安全性事件相关。
要点
- 乌司奴单抗血清浓度与剂量成比例,不受既往生物制剂或免疫调节剂影响。
- 周8浓度阈值3.7 μg/mL与诱导应答相关,稳态谷浓度≥1.3 μg/mL与更高临床缓解率相关。
- 乌司奴单抗浓度与感染、严重感染或严重不良事件无关联。
核心结论
- 乌司奴单抗血清浓度与剂量成比例,不受既往生物制剂或免疫调节剂影响,与临床和组织学疗效及炎症标志物相关,未发现与安全性事件相关。
- 乌司奴单抗在克罗恩病与溃疡性结肠炎患者中的药代动力学一致。
研究设计与样本
- 来自2项3期试验(1项诱导和1项维持)的数据,中重度溃疡性结肠炎患者接受静脉诱导剂量乌司奴单抗130 mg(n=320)或约6 mg/kg(n=322)。
- 应答者随机分配至皮下维持乌司奴单抗90 mg每8周(n=176)或每12周(n=172)或安慰剂(n=175)。
主要发现
- 乌司奴单抗血清浓度与剂量成比例,不受既往生物制剂或伴随免疫调节剂治疗影响,在第二次维持剂量时达到稳态。
- 每8周给药的中位谷浓度约为每12周给药的3倍。
- 血清浓度与临床和组织学疗效特征及炎症标志物(C反应蛋白、粪钙卫蛋白、粪乳铁蛋白)正常化相关。
- 诱导应答的周8浓度阈值为3.7 μg/mL。
- 稳态谷血清浓度≥1.3 μg/mL与较低浓度患者相比临床缓解率更高。
关键数值与推荐
- 诱导应答的周8浓度阈值为3.7 μg/mL。
- 稳态谷血清浓度≥1.3 μg/mL与更高临床缓解率相关。
- 每8周给药的中位谷浓度约为每12周给药的3倍。
临床怎么用
- 监测乌司奴单抗血清浓度可能有助于优化溃疡性结肠炎患者的诱导和维持治疗。
- 周8浓度3.7 μg/mL和稳态谷浓度1.3 μg/mL可作为暴露-反应参考阈值。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The efficacy of antibody-based therapeutics depends on their pharmacokinetics. The pharmacokinetic and exposure response profiles of ustekinumab, a monoclonal antibody against interleukin 12/interleukin 23, are known in patients with Crohn's disease, yet there are few data from patients with ulcerative colitis. We characterized ustekinumab's pharmacokinetics, exposure response, and optimal serum concentrations in patients with ulcerative colitis. METHODS: We collected data from 2 phase 3 trials (1 induction and 1 maintenance), in which patients with moderate to severe ulcerative colitis received an intravenous induction dose of ustekinumab (130 mg, n = 320; or approximately 6 mg/kg, n = 322). Responders were assigned randomly to groups that received subcutaneous maintenance ustekinumab (90 mg) every 8 weeks (n = 176) or 12 weeks (n = 172), or placebo (n = 175). We evaluated the association between ustekinumab concentration and efficacy, serum based on clinical effects (Mayo score), histologic features, and inflammation (measurement of C-reactive protein, fecal calprotectin, and fecal lactoferrin), as well as safety (infections, serious infections, and serious adverse events), during induction and maintenance therapy. Optimal serum concentrations of ustekinumab were identified using receiver operating characteristic curve analyses. RESULTS: In patients with ulcerative colitis, dose-proportional serum concentrations of ustekinumab, unaffected by prior biologic or concomitant immunomodulator therapy, reached steady state by the second maintenance dose; the median trough concentration for dosing every 8 weeks was approximately 3-fold that of dosing every 12 weeks. Serum concentrations were associated with clinical and histologic features of efficacy and normalization of inflammation markers. The week-8 concentration threshold for induction of response was 3.7 μg/mL. A steady-state trough serum concentration of 1.3 μg/mL or higher was associated with a higher rate of clinical remission compared with patients who had lower serum concentrations. Serum concentrations of ustekinumab were not associated with infections, serious infections, or serious adverse events. CONCLUSIONS: In an analysis of data from 2 phase 3 trials of patients with ulcerative colitis, we found that serum concentrations of ustekinumab were proportional to dose, unaffected by prior biologic or concomitant immunomodulator therapies, associated with clinical and histologic efficacy and markers of inflammation, and were not associated with safety events at doses evaluated. Ustekinumab pharmacokinetics are consistent between patients with Crohn's disease vs ulcerative colitis.
引用
- Adedokun OJ, Xu Z, Marano C, et al. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019. PMID: 31816446. doi:10.1016/j.cgh.2019.11.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。